Who
Peter M. Hecht
Director and 10% owner
Company insider
Files Form 4 as: Chief Executive Officer, Cyclerion Therapeutics; Chief Executive Officer, Ironwood Pharmaceuticals.
In numbers
- Trades disclosed
- 166
- Buys
- 5
- Sells
- 16
- Bought
- $5.7M
- Sold
- $10.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Feb 2010
- Last trade
- 16 Jul 2026
- Last filed
- 20 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 20 Jul 2026 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code C | —351,037 | filing |
| 16 Jul 2026filed 20 Jul 2026 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —351,037 | filing |
| 16 Jul 2026filed 20 Jul 2026 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —351,037 | filing |
| 16 Jul 2026filed 20 Jul 2026 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code C | —351,037 | filing |
| 25 Mar 2025filed 27 Mar 2025 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code A | $500K181,818 at $2.75 | filing |
| 1 Jan 2024filed 26 Jan 2024 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Dec 2023filed 4 Dec 2023 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 30 Nov 2023filed 4 Dec 2023 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 19 May 2023filed 22 May 2023 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $3.0M351,037 at $8.68 | filing |
| 19 May 2023filed 22 May 2023 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code A | $2.0M225,000 at $8.68 | filing |
| 20 Jan 2022filed 24 Jan 2022 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —430,000 at $0.00 | filing |
| 3 Jan 2022filed 24 Jan 2022 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,950 at $0.00 | filing |
| 3 Jun 2021filed 7 Jun 2021 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.7M823,170 at $3.28 | filing |
| 6 May 2021filed 10 May 2021 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Bought | $734K302,000 at $2.43 | filing |
| 5 May 2021filed 6 May 2021 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.0M398,001 at $2.53 | filing |
| 4 May 2021filed 6 May 2021 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Bought | $687K300,000 at $2.29 | filing |
| 31 Mar 2020filed 2 Apr 2020 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $408K153,846 at $2.65 | filing |
| 22 Nov 2019filed 26 Nov 2019 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 10 Jul 2019filed 12 Jul 2019 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 10 Jul 2019filed 12 Jul 2019 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K2,000 at $6.04 | filing |
News
No headline names them, or the companies they trade most, lately.